291 related articles for article (PubMed ID: 25483948)
21. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
22. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
23. The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease.
Perry R; Shah R; Saiedi M; Patil S; Ganesan A; Linhart A; Selvanayagam JB
JACC Cardiovasc Imaging; 2019 Jul; 12(7 Pt 1):1230-1242. PubMed ID: 31272606
[TBL] [Abstract][Full Text] [Related]
24. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
25. Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease.
Apelland T; Gude E; Strøm EH; Gullestad L; Eiklid KL; Månsson JE; Reinholt FP; Houge G; Dahl CP; Almaas VM; Heiberg A
Heart; 2014 Nov; 100(22):1793-8. PubMed ID: 25031264
[TBL] [Abstract][Full Text] [Related]
26. Fabry Cardiomyopathy: Current Treatment and Future Options.
Vardarli I; Weber M; Rischpler C; Führer D; Herrmann K; Weidemann F
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300196
[TBL] [Abstract][Full Text] [Related]
27. [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].
Hagège A
Rev Med Interne; 2010 Dec; 31 Suppl 2():S238-42. PubMed ID: 21211672
[TBL] [Abstract][Full Text] [Related]
28. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
29. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
30. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
31. Interdisciplinary approach towards female patients with Fabry disease.
Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
[TBL] [Abstract][Full Text] [Related]
32. Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy.
Yogasundaram H; Kim D; Oudit O; Thompson RB; Weidemann F; Oudit GY
Can J Cardiol; 2017 Jul; 33(7):883-897. PubMed ID: 28668140
[TBL] [Abstract][Full Text] [Related]
33. Myocardial lipid content in Fabry disease: a combined
Petritsch B; Köstler H; Weng AM; Horn M; Gassenmaier T; Kunz AS; Weidemann F; Wanner C; Bley TA; Beer M
BMC Cardiovasc Disord; 2016 Oct; 16(1):205. PubMed ID: 27793097
[TBL] [Abstract][Full Text] [Related]
34. Right ventricular involvement in patients with Fabry's disease and the effect of enzyme replacement therapy.
Wuest W; Machann W; Breunig F; Weidemann F; Koestler H; Hahn D; Wanner C; Beer M
Rofo; 2011 Nov; 183(11):1037-42. PubMed ID: 21959886
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
36. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
37. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
38. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
Chen KH; Chou YC; Hsiao CY; Chien Y; Wang KL; Lai YH; Chang YL; Niu DM; Yu WC
Biochem Biophys Res Commun; 2017 Apr; 486(2):293-299. PubMed ID: 28300554
[TBL] [Abstract][Full Text] [Related]
39. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
40. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy.
Shah JS; Elliott PM
Acta Paediatr Suppl; 2005 Mar; 94(447):11-4; discussion 9-10. PubMed ID: 15895705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
